Adma Biologics (ADMA) Current Leases (2011 - 2025)

Adma Biologics' Current Leases history runs 14 years deep, the most recent figure standing at $1.1 million for Q4 2025.

• Quarterly Current Leases fell 10.02% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (down 10.02% YoY) and the FY2025 annual result came in at $1.1 million, down 10.02% from the prior year.
• Current Leases was $1.1 million for Q4 2025 at Adma Biologics, down from $1.3 million in the prior quarter.
• Across five years, Current Leases topped out at $1.3 million in Q3 2025 and bottomed at $317910.0 in Q1 2021.
• A 5-year average of $898699.1 and a median of $981213.5 in 2023 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2022 — Current Leases jumped 105.72% — and 2025, when it declined 10.02%.
• Adma Biologics' Current Leases stood at $591084.0 in 2021, then surged by 53.11% to $905000.0 in 2022, then rose by 15.47% to $1.0 million in 2023, then advanced by 16.56% to $1.2 million in 2024, then slipped by 10.02% to $1.1 million in 2025.
• Business Quant data shows ADMA's Current Leases at $1.1 million in Q4 2025, $1.3 million in Q3 2025, and $1.1 million in Q2 2025.